Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025

Depreciation & amortization of CN¥13.45M in Q4 FY2025

Q4 FY2025 depreciation & amortization was CN¥13.45M. Over 3 fiscal years it compounded at +11.3% a year.

Context

  • Depreciation & amortization amounted to 22.3% of revenue in FY2025, up 9.3 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥13.45M+97.3% QoQ
Last fiscal yearDec 2025
CN¥25.96M+7.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+7.4%——
3-year CAGR+11.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CNY · from the income statement

Latest · FY2025
25.96M CNY
Year-over-year change
+7.4%
4-year CAGR
+12.8%

Depreciation & Amortization vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.4% is the 4th highest of 9, against a peer median of -30.0%.
  • Depreciation & amortization amounts to 22.3% of revenue for ZYBT, versus a peer median of 3.6%.
ZYBT Competitors
Depreciation & Amortization for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥25.96M CNY+7.4%+11.3%22.3%
PDEXPro-Dex, Inc.LTM Mar 2026$2.28M USD+85.2%+19.5%3.1%
SERASera Prognostics, Inc.LTM Mar 2026$917K USD+9.7%+7.5%1608.8%
APYXApyx Medical CorporationLTM Mar 2026$687K USD+18.4%-9.7%1.2%
SRZNSurrozen, Inc.LTM Mar 2026$308K USD-77.1%-35.0%4.1%
EXOZeXoZymes, Inc.LTM Mar 2026$291.61K USD+6.0%+24.9%—
TILInstil Bio, Inc.LTM Mar 2026$291K USD-90.7%-55.3%—
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$103.77K CAD-66.0%-14.3%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$75.25K CAD-79.8%-31.7%—
Peer median (excluding ZYBT) —-30.0%-12.0%3.6%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue214.07M260.27M211.65M186.36M116.36M
Cost of Revenue88.67M106.75M81.8M95.06M92.49M
Gross Profit125.39M153.52M129.86M91.3M23.87M
Gross Margin58.6%59.0%61.4%49.0%20.5%
Research & Development11.37M13.42M11.9M12.79M18.01M
Selling, General & Admin58.19M63.56M66.63M63.84M74.92M
Operating Expenses73.01M87.69M84.87M74.86M92.12M
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
EBITDA70.12M85.55M72.1M42.6M(42.52M)
EBITDA Margin32.8%32.9%34.1%22.9%-36.5%
Operating Income52.38M65.83M44.99M16.44M(68.25M)
Operating Margin24.5%25.3%21.3%8.8%-58.7%
Interest Income112K114K312K231K96K
Interest Expense1.05M2.84M4.42M4.04M3.4M
Other Income / Expenses683K(1.92M)(1.22M)(2.05M)(3.62M)
Income Before Tax53.07M63.91M43.76M14.39M(71.87M)
Pre-Tax Margin24.8%24.6%20.7%7.7%-61.8%
Income Tax Expense6.6M8.17M6.25M924K11.1M
Net Income38.96M46.74M31.46M11.31M(69.78M)
Net Margin18.2%18.0%14.9%6.1%-60.0%
EPS (Basic)0.851.020.690.24(1.40)
EPS (Diluted)0.830.990.670.24(1.40)
Weighted Avg Shares45.67M45.67M45.67M47.17M47.35M
Weighted Avg Shares (Diluted)47.17M47.17M47.17M47.17M47.35M

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.